Efficacy and safety of beloranib for weight loss in obese adults: A randomized controlled trial

D.D. Kim, J. Krishnarajah, S. Lillioja, F. De Looze, J. Marjason, J. Proietto, S. Shakib, Bronwyn Stuckey, J.E. Vath, T.E. Hughes

    Research output: Contribution to journalArticle

    41 Citations (Scopus)

    Abstract

    © 2015 John Wiley & Sons Ltd. Aim: To assess the efficacy, safety and tolerability of beloranib treatment for obesity. Methods: This phase II, double-blind, randomized study investigated the effects of beloranib suspension (0.6, 1.2 and 2.4mg) or placebo, administered subcutaneously, for 12weeks in 147 participants (primarily white women) with obesity. No diet or exercise advice was administered. Results: At week 12, beloranib resulted in dose-dependent progressive weight loss of -5.5±0.5, -6.9±0.6 and -10.9±1.1kg for the 0.6, 1.2 and 2.4mg beloranib doses, respectively, compared with -0.4±0.4kg with placebo (all p
    Original languageEnglish
    Pages (from-to)566-572
    JournalDiabetes, Obesity and Metabolism
    Volume17
    Issue number6
    DOIs
    Publication statusPublished - 2015

    Fingerprint Dive into the research topics of 'Efficacy and safety of beloranib for weight loss in obese adults: A randomized controlled trial'. Together they form a unique fingerprint.

    Cite this